|
|
| (2 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{SI}}
| |
| {{WikiDoc Cardiology Network Infobox}}
| |
|
| |
|
|
| |
| Stent thrombosis (ST) is a rare but devastating complication of coronary artery stenting that is associated with a high rate of morbidity and mortality <ref>Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71.</ref> <ref>Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 1997;29:6-12.</ref> <ref>Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation 1996;94:1519-27.</ref>
| |
| <ref>Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol 2002;40:1567-72. </ref>
| |
|
| |
| Over the years stent thrombosis of bare metal stents (BMS) has been minimised by refining stent design, adopting optimal stenting strategies and improved antiplatelet medication usage from a massive 24% in some studies to <ref>Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF, Meier B, Goy JJ, Vogt P, Kappenberger L. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991;324:13–17.</ref> a rare and acceptable 0.5-1.5% in the current environment.
| |
|
| |
| Following the approval by the FDA, the drug eluting stents (DES) largely replaced BMS, driven solely by the reduced revascularization with relatively little attention paid to the issue of ST.
| |
|
| |
| Increased usage of DES and continued presentation of paients with ST beyond the first few months of implantation, coupled with the widespread awareness of ST, have led to a steady and increased stream of reporting of ST in DES.
| |
|
| |
| Recent description of frequent subclinical insitu thrombus formation within DES in the coronaries by Katani et al, not only took the medical community by surprise but afforded a first hand in-vivo glimpse at the stent site itself. It should be noted that the term coronary stent thrombosis (ST) is commonly used for clinically significant episodes. <ref>Sotirios Tsimikas, Drug-Eluting Stents and Late Adverse Clinical Outcomes; Lessons Learned, Lessons Awaited; editorial comment; JACC Vol. 47, No. 10, 2006</ref> <ref>Kotani, J, Awata, M, Nanto, S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006; 47:2108.</ref>
| |
|
| |
| In this context, clinically significant ST appears to be a rare complication with devastating consequences if left untreated emergently, though the mileu for such probably exists in a much larger population.
| |
|
| |
| This process should not be confused with restenosis, a fibro-proliferative disorder which is associated with recurrent angina and ischemia but uncommonly with myocardial infarction or death.
| |
|
| |
|
| |
| ==References==
| |
| {{reflist|2}}
| |